Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

Houston Metro Urology

Neither a doctor nor a teaching hospital

Research payments

$11,834,123

329 payments

Through program year 2025, Houston Metro Urology is reported as receiving $11,834,123 in research payments, across 329 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $1,871,110 45
2024 Research $2,318,770 55
2023 Research $1,065,906 21
2022 Research $1,417,635 38
2021 Research $2,513,766 44
2020 Research $1,857,471 69
2019 Research $789,466 57

Breakdown

Who paid Research payments · program years 2019–2025
  1. Pfizer Inc. $5,887,638 150 payments
  2. Medivation Inc. $2,791,876 49 payments
  3. Palette Life Sciences, Inc. $1,762,681 10 payments
  4. Merck Sharp & Dohme Corporation $909,430 13 payments
  5. Coloplast Corp $112,744 16 payments
  6. Astellas Pharma Global Development $96,490 19 payments
  7. Teleflex LLC $88,090 3 payments
  8. OPKO Pharmaceuticals, LLC $36,276 9 payments
  9. Ortho-Clinical Diagnostics, Inc. $31,303 2 payments
  10. Exelixis Inc. $29,424 6 payments
Studies the money was for Research payments · program years 2019–2025
  1. A Phase 3 Randomized Efficacy and Safety Study of Enzalutamide Plus Leuprolide Enzalutamide Monotherapy and Placebo Plus Leuprolide in Men With Highrisk Nonmetastatic Prostate Cancer Progressing After Definitive Therapy $4,384,257 84 payments
  2. Talapro3 A Phase 3 Randomized Doubleblind Study of Talazoparib With Enzalutamide Versus Placebo With Enzalutamide in Men With DDR Gene Mutated Metastatic Castrationsensitive Prostate Cancer $1,962,264 25 payments
  3. Randomized Trial of Barrigel $1,576,123 7 payments
  4. A Phase 3 Randomized Doubleblind Placebocontrolled Study of Talazoparib With Enzalutamide in Metastatic Castrationresistant Prostate Cancer $756,487 15 payments
  5. A Phase 3 Randomized Doubleblind Placebocontrolled Study of Talazoparib in Combination With Physicians Choice of Enzalutamide Or Abiraterone Acetateprednisone in Metastatic Castrationresistant Prostate Cancer With Dna Damage Repair Deficiencies $670,420 15 payments
  6. A Phase 3, Randomized, Comparator-controlled Clinical Trial to Study the Efficacy and Safety of Pembrolizumab MK-3475 in Combination with Bacillus Calmette- Guerin BCG in Participants with High-risk Non-muscle Invasive Bladder Cancer HR NMIBC that is either Persistent or Recurrent Following BCG Induction or that is Na to BCG Treatment KEYNOTE-676 $500,830 8 payments
  7. A Phase 3 Randomized Doubleblind Placebocontrolled Study of Talazoparib in Combination With Physicians Choice of Enzalutamide Or Abiraterone Acetateprednisone in Metastatic Castrationresistant Prostate Cancer With Dna Damage Repair Deficiencies $457,407 27 payments
  8. A Phase 3 Randomized Doubleblind Placebocontrolled Study of Talazoparib With Enzalutamide in Metastatic Castrationresistant Prostate Cancer $414,015 23 payments
  9. A Phase 3, Randomized, Comparator-controlled Clinical Trial to Study the Efficacy and Safety of Pembrolizumab MK-3475 in Combination with Bacillus Calmette- Guerin BCG in Participants with High-risk Non-muscle Invasive Bladder Cancer HR NMIBC that is either Persistent or Recurrent Following BCG Induction or that is Na ve to BCG Treatment KEYNOTE-676 $197,013 3 payments
  10. Randomized Trial of Barrigel $186,559 3 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record